芬太尼／哌替啶致Oddi括约肌痉挛的探讨

２００例择期胆囊切除＋术中胆道造影患者分二组；芬太尼１７ｕｇ／ｋｇ静注（Ｆ组，ｎ＝１００）、哌替啶１ｍｇ／ｋｇ静注。评价两种麻醉性镇痛药致Ｏｄｄｉ括约肌痉挛的发生率，结果：８例病人造影剂不能通过Ｏｄｄｉ括约肌、十二指肠不显影，胆总管下端显示“鸟嘴样”或“假结石”影像，后者３例病人胆总管探查阴性，静注纳络酮０．４ｍｇ后，全部病例造影剂顺利进入十二指肠。结论：硬膜外麻醉辅用小剂量芬太尼／哌替啶时Ｏｄｄ     

维拉帕米灌注治疗前列腺术后膀胱痉挛性疼痛的临床疗效观察

为探讨前列腺术后膀胱痉挛性疼痛的药物治疗效果，将２６例前列腺增生行耻骨上经膀胱前列腺摘除术后频繁发作膀胱逼尿肌无抑制性收缩导致膀胱痉挛性疼痛者，按随机抽样法分为两组，第１组１５例接受维拉帕米膀胱灌注治疗，第２组１１例作为对照，不用任何可能影响下尿中功能的药物。     

遗传性痉挛性共济失调——附1家族4代9例报告

[目的 ]探讨遗传性痉挛性共济失调的家族生育的危害 .[方法 ]对一家族 4代系谱进行分析 .[结果 ]遗传性痉挛性共济失调为常染色体显性遗传性疾病 .[结论 ]遗传性痉挛性共济失调的家族成员应采取节育措施     

面肌痉挛显微血管减压术中异常肌反应监测价值研究

目的探讨异常肌反应(AMR)监测在鉴别责任血管、评估减压效果以及判断预后方面的作用。方法24例面肌痉挛患者接受了术中AMR监测的研究,麻醉诱导后不使用肌松剂。采取刺激面神经颧支,记录同侧颏肌电反应的方法,分析AMR监测结果与术后疗效的关系。结果术中所有患者均记录到特征性的AMR波形。面神经根减压后AMR消失20例,AMR未消失4例。AMR消失的20例患者术后1周17例患者面肌痉挛消失,随访结果20例患者面肌痉挛消失。术中AMR未消失的4例患者术后1周1例患者面肌痉挛消失,随访结果2例患者面肌痉挛消失。经统计学分析AMR消失组的疗效明显好于AMR未消失组。结论术中AMR监测有助于鉴别责任血管,评估即刻减压效果,有助于判断手术的预后,能够显著提高面肌痉挛患者手术的长期效果。     

选择性臂丛神经根切断治疗上肢痉挛脑瘫的远期疗效评价

目的评价选择性臂丛神经根切断治疗上肢痉挛性脑瘫的远期疗效。方法对1997年3月-2002年1月间施行选择性臂丛神经根切断术治疗上肢痉挛性脑瘫的患者，进行随访并对远期功能进行评价，采用Lazareg肌张力分级标准评定临床效果。结果16例17侧获得随访，随访时间为5．0～9．7年，平均8．6年。手术方式为选择性臂丛神经根全根切断10侧，部分切断2侧，高选择性分束切断5侧；其中切断神经根为颈63次，颈816次。术后远期疗效优3例，有效5例，无效8例9侧。结论选择性臂丛神经根切断治疗上肢痉挛性脑瘫远期大多数疗效下降和无效，但术前严格选择痉挛较局限的病例、术中进行高选择性臂丛神经根分束切断、术后坚持长期康复训练仍然能获得较好的疗效。     

应用改进封闭脊髓窗技术活体观察脊髓损伤后脊髓微循环变化

目的:探讨应用改进的封闭脊髓窗技术活体观察大鼠脊髓损伤后脊髓微循环变化的可行性及效果.方法:改进传统的脊髓窗,设计带有打击探头的脊髓窗.45只SD大鼠随机分为对照组(n=20)和实验组(n=25).实验组大鼠脊髓窗安装完成后进行窗内打击脊髓,然后即时观察并记录打击后2h内打击点周围微动脉直径的变化.对照组大鼠在脊髓窗安装完成后不进行打击,只对脊髓微动脉直径进行连续2h观察并记录.术后两组大鼠进行BBB运动功能评分,处死动物取脊髓标本切片,HE染色,观察脊髓组织改变情况.结果:实验组大鼠打击点周围2～6mm的微动脉直径在打击后10min、30min、1h、2h各时间点均较打击前明显减小,术后2d及7d时BBB功能评分明显低于术前,病理切片可见脊髓打击区神经组织变性液化.对照组大鼠在观测开始及结束时脊髓微动脉直径无明显变化,术后BBB评分与术前BBB评分均为21分,病理切片未见脊髓损伤表现.结论:改进的封闭脊髓窗技术可以有效地实现窗内打击脊髓,并可以安全地对脊髓表面微血管进行活体观测.脊髓表面打击点周围2～6mm的微动脉在脊髓损伤后10min即发生痉挛.     

Fatal encephalitis in a patient with refractory celiac disease presenting with myorhythmia and carpal spasm.

We report the case of a woman with refractory celiac disease who developed abnormal spontaneous movements of the extremities and face consistent with myorhythmia. Investigation led to a diagnosis of encephalitis, confirmed by postmortem examination. The movements were likely caused by nonparaneoplastic encephalitis associated with refractory celiac disease. Etiologic and diagnostic considerations and treatment options are discussed.     

Asynchronous blepharospasm, facial and cervical dystonia, and bilateral asynchronous hemifacial spasm.

We present a patient with a facial movement disorder that has characteristics of both blepharospasm and bilateral asynchronous hemifacial spasm. Because of the increased incidence of blepharospasm in patients with hemifacial spasm, our patient's clinical presentation is probably not a chance occurrence, but rather a manifestation of some predisposition for these two movement disorders. This unusual constellation of signs and symptoms challenges the current diagnostic criteria and suggests that some of these facial movement disorders may lie on a spectrum, rather than represent distinct entities.     

Microvascular decompression for hemifacial spasm: postoperative neurologic follow-up and evaluation of life quality

Microvascular decompression (MVD) is an effective and safe treatment in hemifacial spasm (HFS). Postoperative evaluations are usually made by neurosurgeons. Follow-up studies performed by neurologists and postoperative quality of life (QoL) investigations are lacking. All 25 HFS patients operated with MVD in our centre between 2000 and 2004 were evaluated with the recently validated HFS-7 scheme, extended with the item 'sleep disturbance due to HFS' (HFS-8). The patients underwent a careful neurological examination median 3 years after the operation. The evaluation focused on clinical aspects, changes in blood pressure and time until observable effect of MVD. The evaluation of HFS-7 questionnaire and the extended form (HFS-8) showed significant improvement in QoL after MVD. Neurological outcome was in almost all cases excellent or good. Eleven (44%) patients had no neurological deficits at all. Only one patient had serious complications with ipsilateral facial palsy, deafness, balance problems and vertigo. The other patients had minor neurological findings or symptoms. Eighteen (72%) patients experienced early effect within 3 months after MVD; seven (28%) patients had late effect between 6 and 14 months. Median age of the patients with late effect (62.6 years) was significantly higher than in those with early effect (52.7 years).